Incyte Corporation (INCY)
NASDAQ: INCY · Real-Time Price · USD
113.27
+1.70 (1.52%)
At close: Oct 15, 2026, 4:00 PM EDT
113.27
0.00 (0.00%)
After-hours: Oct 15, 2026, 5:13 PM EDT
Incyte Revenue
Incyte had revenue of $1.67B in the quarter ending June 30, 2026, with 37.72% growth. This brings the company's revenue in the last twelve months to $5.82B, up 26.93% year-over-year. In the year 2025, Incyte had annual revenue of $5.14B with 21.22% growth. That makes Incyte the 2,320th largest company in the world by revenue and 675th in the United States.
Revenue (ttm)
$5.82B
Revenue Growth
+26.93%
P/S Ratio
3.97
Revenue / Employee
$2,046,248
Employees
2,844
Market Cap
22.96B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.14B | 900.03M | 21.22% |
| Dec 31, 2024 | 4.24B | 545.57M | 14.76% |
| Dec 31, 2023 | 3.70B | 301.01M | 8.87% |
| Dec 31, 2022 | 3.39B | 408.37M | 13.67% |
| Dec 31, 2021 | 2.99B | 319.57M | 11.98% |
| Dec 31, 2020 | 2.67B | 507.94M | 23.53% |
| Dec 31, 2019 | 2.16B | 276.88M | 14.71% |
| Dec 31, 2018 | 1.88B | 345.67M | 22.50% |
| Dec 31, 2017 | 1.54B | 430.50M | 38.93% |
| Dec 31, 2016 | 1.11B | 351.97M | 46.70% |
| Dec 31, 2015 | 753.75M | 242.26M | 47.36% |
| Dec 31, 2014 | 511.50M | 508.45M | 16,696.72% |
| Dec 31, 2013 | 3.05M | -294.01M | -98.97% |
| Dec 31, 2012 | 297.06M | 202.60M | 214.50% |
| Dec 31, 2011 | 94.46M | -75.42M | -44.40% |
| Dec 31, 2010 | 169.88M | 160.61M | 1,733.55% |
| Dec 31, 2009 | 9.27M | 5.35M | 136.41% |
| Dec 31, 2008 | 3.92M | -30.52M | -88.62% |
| Dec 31, 2007 | 34.44M | 6.80M | 24.59% |
| Dec 31, 2006 | 27.64M | 19.80M | 252.32% |
| Dec 31, 2005 | 7.85M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Alnylam Pharmaceuticals | 4.80B |
| Jazz Pharmaceuticals | 4.60B |
| Genmab | 4.13B |
| BioNTech SE | 3.03B |
| Royalty Pharma | 2.54B |
| Exelixis | 2.44B |
| Halozyme Therapeutics | 1.66B |
| Ascendis Pharma | 1.20B |
INCY News
- 1 day ago - Incyte price target raised to $115 from $105 at Truist - TheFly
- 2 days ago - Incyte Honors the 2026 MPN Heroes®, Celebrating Champions of the Myeloproliferative Neoplasm (MPN) Community - Business Wire
- 7 days ago - Incyte price target raised to $114 from $109 at RBC Capital - TheFly
- 7 days ago - Incyte to Report Third Quarter Financial Results - Business Wire
- 9 days ago - Knight Therapeutics Announces Regulatory Approval of NIKTIMVO® in Brazil - GlobeNewsWire
- 10 days ago - Incyte price target raised to $157 from $145 at Stifel - TheFly
- 17 days ago - Incyte management to meet with Oppenheimer - TheFly
- 17 days ago - Incyte price target raised to $123 from $120 at JPMorgan - TheFly